Smart Multimedia Gallery
SINGAPORE & JAKARTA, Indonesia
Quintiles today announced the start of its first global study involving Indonesia, made possible by an exclusive alliance with Prodia Clinical Laboratory to provide high quality in-country testing of samples from Indonesian patients in clinical trials.
Alan Ong, Vice President & General Manager, Southeast Asia, Quintiles (Photo: Business Wire)
With a population of more than 240 million, Indonesia has been difficult to include in global trials because of requirements that all local samples be tested in-country before samples or data can be exported. Two things changed that: Prodia’s exclusive alliance with Quintiles to test trial samples; and its recent accreditation by the College of American Pathologists, the world’s foremost organization dedicated to laboratory quality improvement.
“We have embarked on a new chapter for clinical research in Indonesia with the placement of our first study there using Prodia’s CAP-accredited harmonized central laboratory,” said Alan Ong, Vice President and General Manager of Quintiles Southeast Asia. “Indonesia is now part of a diabetes study that’s expected to enroll about 14,000 patients globally. This is testament to Quintiles’ commitment to obtain evidence of the potential benefits of new medicines in patient populations for whom they are intended.”
In November 2011, Quintiles announced an exclusive partnership with Jakarta-based Prodia Clinical Laboratory, through its sister company Prodia the CRO, giving Quintiles exclusive access to Prodia’s central laboratory for a two-year period, beginning with the first study in place.
Endang Hoyaranda, President Director of Prodia Group, said, “Prodia is proud to partner with Quintiles in establishing Indonesia as a regional hub for clinical trials. As the local market leader and only CAP-accredited central laboratory in Indonesia, Prodia is playing a significant role in helping establish Indonesia as a clinical trial center of excellence.”
Indonesia’s large, ethnically diverse population faces a wide range of infectious and non-communicable diseases, making it a promising location to conduct clinical trials needed to bring new, better medicines to patients in need. Quintiles first opened an office in Indonesia (Jakarta) in 2006.
About Quintiles
Quintiles is the world’s leading provider of biopharmaceutical services. With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences customers navigate the increasingly complex landscape with more predictability to enable better outcomes.
About Prodia Clinical Laboratory
Prodia Clinical Laboratory, one of the largest and the best clinical laboratories in Asia for nearly 39 years, provides a wide range of laboratory testing services. Quality is first priority from the time subjects are prepared for specimen collection up to final data analysis. Prodia was the first clinical laboratory in Indonesia to meet with ISO 9001 & ISO 15189 standards, and has recently obtained certification from the National Glycohemoglobin Standardization Program (NGSP) Level 1 for HbA1c standardization, and most recently was accredited by the College of American Pathologists. It has received awards as National Top Brand for three consecutive years, and owns a network of 110 branches nationwide to cover patient sampling at any needed site in the country. It has been working in the clinical trial area for nearly 15 years, and later established a sister CRO company. To learn more about Prodia Labs and Prodia the CRO, visit their websites at www.prodiathecro.com and www.prodia.co.id.
Click here to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50430627&lang=en
CONTACT
Quintiles
Media Relations:
Jessie Lee, +65 6602 1576
mobile:
+65 8181 3805
jessie.lee@quintiles.com
or
Investor
Relations:
Greg Connors, +1 919-998-2000
invest@quintiles.com
